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ABSTRACT: The influence of experimentally induced hepatic dysfunc-
tion on the pharmacokinetics of Cydosporine A (CsA) was determined in 
dogs. The pharmacokinetics of oral (PO) and intravenous (IV) CsA were 
studied before and after 70 per cent hepatectomy or complete bile duct 
ligation (CBDL). Changes in liver function were monitored by serial 
measurements of serum bilirubin, and by the maximum removal rate 
(Rmax) and plasma disappearance rate (ICG-K) of indocyanine green 
(ICG). Concentrations of CsA in whole blood were measured by HPLC. 
Seventy per cent hepatectomy caused significant liver dysfunction: the ICG-
Rmax decreased by 47.7 ± 7.1 per cent (mean ± SD) and the ICG-K 
decreased by 6l.3 ± 9.7 per cent during the first week after hepatectomy. At 
the same time, the systemic dearance (CLs) of IV-CsA decreased by 43.9 ± 
8.2 per cent, the area under the concentration curve (AVC) of IV-esA 
increased by 35.4 ± 20.8 per cent and the bioavailability of CsA decreased by 
26.4 ± 14.8 per cent. CBDL also induced significant liver dysfunction: the 
ICG-Rmax decreased by 39.1 ± 12.8 per cent and the ICG-K decreased by 
65.6 ± 3.6 per cent in the second week after the operation. During the same 
period, the AVC of PO-CsA decreased by 69.9 ± 10.7 per cent and the 
bioavailability of CsA also decreased markedly by 73.9 ± 15.6 per cent. 
These data indicate that hepatic impairment significantly influences the 
pharmacokinetics of CsA, not only by the changes in intestinal absorption, 
but also by those in hepatic metabolism. Dose adjustment is therefore 
necessary in the presence of hepatic dysfunction in order to maintain an 
adequate blood concentration of CsA without causing side effects. 
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INTRODUCTION 
Therapy with cydosporine A (CsA) con-
stitutes a major advance which has led to the 
success of orthotopic liver transplantation 
(OLTX) and other organ transplantations. 
OLTX in particular presents special prob-
lems regarding the maintenance of adequate 
pharmacological immunosuppression. The 
absorption, distribution, metabolism, elimi-
nation and excretion of CsA can be expected 
to be significantly altered by the transplanta-
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tion procedure, as the liver is a major site of 
the metabolism and elimination of CsA, and 
also because this organ is related to its 
absorption. The status of the liver therefore 
greatly influences CsA pharmacokinetics. 
The assessment of dose adjustment neces-
sary, however, is quite difficult because rou-
tine hepatic function tests do not correlate 
with CsA elimination. 1 It is therefore impor-
tant to devise a more accurate quantitative 
method of assessing liver function, utilizing 
the kinetics of indocyanine green (ICG) 
removal from the blood. In the present study, 
we investigated the pharmacokinetics of in-
travenous and oral CsA following various 
degrees of hepatic dysfunction created by 
either 70 per cent hepatectomy or complete 
bile duct ligation in dogs. 
MATERIALS AND METHODS 
Thirteen healthy adult mongrel dogs, 
weighing 19.0 to 24.0 kg, were fasted for 18 
hours preoperatively. Anesthesia was in-
duced with pentobarbital and respiration was 
maintained by a respirator with room air 
ventilated through a cuffed endotracheal 
tube. Resection of about 70 per cent of the 
liver was performed in 6 dogs, according to 
the procedure described by Sigel.2 This pro-
cedure of approximately a 70 per cent 
hepatectomy was carried out by resecting the 
right central, quadrate, left central and left 
lateral lobes, according to the classification 
of Price et al.3 The caudate and right lateral 
lobes were left. A complete bile duct ligation 
was performed in 7 dogs: The bile duct was 
ligated doubly and cut between the ties. 
Cyclosporine administration, assay and phar-
macokinetical analysis 
CsA pharmacokinetics were studied in all 
13 dogs. Each dog received 2 mg/kg of CsA 
as an intravenous continuous infusion over 1 
hour, using a calibrated pump in order to 
maintain a constant rate of infusion, and 
17.5 mg/kg of CsA (Sandimmune Oral Solu-
tion) orally, after an interval of a 3 day 
washout period. After the 70 per cent 
hepatectomy, intravenous or oral CsA was 
given for the pharmacokinetic study during 
the first postoperative week. Mter the com-
plete bile duct ligation, the study of CsA 
kinetics was performed during the second 
postoperative week. Blood samples of 3 ml 
were collected from the jugular veins, before 
and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 
hours after drug administration, for the study 
of intravenous CsA kinetics, and 0, 1, 2, 3, 4, 
6,8, 12, 16 and 24 hours after drug adminis-
tration for the oral CsA kinetics. 
The CsA blood concentration in whole 
blood was measured using a high-perform-
ance liquid chromatographic assay (HPLC) 
by the method of Sawchuk and Cartier.4 
Pharmacokinetic parameters were calcu-
lated using a model-independent analysis. 
The terminal disposition rate constant (Kel) 
was determined by the least square linear 
regression analysis of the terminal phase of 
the blood concentration versus time curve. 
The area under the blood concentration 
versus time curve (AUC) was calculated using 
a trapezoidal rule. The computer "Moments" 
was used to calculate the model-independent 
parameters, which included the total body 
clearance (CLs), the mean residence time 
and the steady-state volume of distribution 
(Vss). The bioavailability (percentage F) of 
oral CsA was calculated using the following 
equation. 
Bioavailability 
(percentage F) 
Aue of oral esA 
AUe of intravenous esA X 
Dose of intravenous esA 
Dose of oral esA X 100 
Kinetics of ICG removal from the blood 
In order to estimate the ICG plasma dis-
appearance rate (ICG-K) using the ICG dose 
of 0.5 mg/kg body weight, and to measure 
the ICG maximal removal rate (ICG-Rmax) 
using ICG doses of 0.5 mg/kg and 5.0 mg/kg 
body weight, Moody and Rikkers' method5 
was used with some modification. ICG-K 
relates to effective hepatic blood flow, and 
ICG-Rmax is one of the most accurate para-
meters of hepatic functional reserve.6 The 
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study of the kinetics of ICG removal was 
performed on a different day from that of 
CsA kinetics. During the analysis of ICG 
kinetics, each dog was placed in a Pavlov 
frame. ICG in doses of 0.5 or 5.0 mg/kg was 
then injected intravenously into one foreleg, 
while sequential blood samples were ob-
tained from the opposite leg 3, 5, 7, 10 and 15 
minutes after the injection. The ICG con-
centration of the plasma fraction of these 
samples was determined spectrophotometri-
cally at a wave length of 805 nm, after 
appropriate dilution with normal saline. 
Based on these data, ICG-K was determined 
by the least square linear regression analysis 
of the ICG blood concentration versus time 
curve. ICG-Rmax was calculated by applying 
the Michaelis Menten equation and a Line-
weaver-Burk plot of the double-reciprocal 
relationship between the administered dose 
and the removal rate of ICG was used.7 
Regression analysis was perlormed to test the 
applicability of this formula to our data. 
Serum chemical studies 
Semm chemical studies, such as semm 
bilirubin, glutamic oxaloacetic transaminase 
(SCOT) and prothrombin time, were mea-
sured in all dogs. The body weight and 
hematocrit values were checked before and 
after surgery, and on the day of investigation. 
Data analysis 
Results are represented by the mean ± 
standard deviation and analyzed by the 
paired Student's t-test for ICG kinetics and 
the unpaired Student's t-test for CsA kinetics. 
A p-value of less than 0.05 was considered 
statistically significant. 
RESULTS 
The 70 per cent hepatectomy did not result 
in immediate mortality of any of the 6 dogs, 
although the complete bile duct ligation 
resulted in an over-all mortality rate of 14 per 
cent (117) of the 7 dogs, occurring within 2 
weeks after the operation. 
The CsA concentration-time curves were 
adequately described by a two-compartment 
Table 1. The Kinetics of ICG Removal 
and Serum Bilirubin Levels According 
to the Liver Function after 70 Per cent 
Hepatectomy in Dogs 
Parameters of ICG Control 70% Hepatectomy 
kinetics (n=6) (n=6) 
ICG-Rmax 0.377±0.046 0.1 58±0.028 
(mg/kg/min) p<O.OOI 
ICG-K 0.092±0.01l 0.035±0.008 
( /min) p<O.OOI 
Serum Bilirubin 0.30 ±0.08 0.71 ±0.17 
(mg/dl) p<0.05 
ICG-Rmax: the maximal removal rate of indocy-
anine green 
ICG-K: the plasma disappearance rate of indo-
cyanine green 
Results are represented by mean ± standard 
deviation and analysed by the paired Student's 
t-test. A p-value of less than 0.05 was considered 
statistically significant, when comparing control 
and hepatectomy results. 
Table 2. The Kinetics of ICG Removal 
According to the Liver Function and 
Serum Bilirubin Level after Complete 
Bile Duct Ligation in Dogs 
Parameters of ICG Control Bile duct ligation 
kinetics (n=6) (n=6) 
ICG-Rmax 0.357±0.049 0.215±0.047 
(mg/kg/min) p<0.005 
ICG-K 0.088±0.009 0.029±0.004 
( /min) p<O.OOI 
Serum bilirubin 0.29 ±0.09 5.80 ±2.80 
(mg/dl) p<0.001 
ICG-Rmax: the maximal removal rate of indo-
cyanine green 
ICG-K: the plasma disappearance rate of indo-
cyanine green 
Results are represented by mean ± standard 
deviation and analysed by the paired Student's 
t-test. A p-value of less than 0.05 was considered 
statistically significant when comparing control 
and bile duct ligation results. 
first order pharmacokinetic model. Tables 1, 
2 and 3 summarize the pharmacokinetic 
parameters of CsA and the kinetics of ICC 
removal, derived from the blood con centra-
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Table 3. Phannacokinetic Parameters of CsA Following 70 Per cent Hepatectomy 
or Complete Bile Duct Ligation in Dogs 
Pharmacokinetic parameters 
of intravenous CsA Control Hepatectomy Bile but ligation 
t1l2 (hrs) 5.06±1.l6* 7.65±1.44** 8.32±3.41 
p<O.05 
CLs (mllmin/kg) 7.09±2.l0* 3.85±0.61 ** 5.37±0.92*** 
p<0.05 p<0.05 
Vss (lIkg) 2.80±l.lO 2.57±O.61 2.64±O.69 
AUC (ng'hr/ml) 5100±1471* 7311±1462** 5842±1l24 
Phannacokinetic parameters 
of oral CsA 
2.74±1.68 
p<0.05 
5.35±2.17 12.7±9.50 t1l2 abs (hr) 
AUC (ng'hr/ml) 8382±1815* 10037±656 2602±898*** 
p<O.OOl 
%F (%) 21.8±4.4* 16.0±3.2** 5.7±3.4*** 
p<0.05 p<O.OOl 
CsA phannacokinetic parameters, t1l2; tenninal halflife, CLs; total body clearance of CsA, Vss; 
steady state volume of distribution, AUC; area under CsA concentration versus time curve, %F; 
per cent bioavailability of oral CsA. 
Results are represented by mean ± standard deviation and analysed by the unpaired Student's 
t-test. A p-value ofless than 0.05 was considered statistically significant, when comparing control 
and hepatectomy results (* VS **), and when comparing control and bile duct ligation results 
(* VS ***). 
tion versus time. The control value was taken 
from the data in the preoperative periods. 
Each parameter was examined during the 
first postoperative week after hepatectomy in 
6 dogs, and in the second week after bile duct 
ligation in 6 dogs. 
In the preoperative control study, the 
mean CLs of intravenous CsA was 7.09 ± 
2.10 (ranging from 4.38 to 8.90) mIl min/kg 
and the mean bioavailability of oral CsA was 
21.8 ± 4.4 (ranging from 15.5 to 26.3) per 
cent. The maximal CsA concentration of 
intravenous and oral CsA were 1671 ± 715 
(ranging from 654 to 2600) ng/ml and ll05 
± 174 (ranging from 800 to 1293) ng/ml, 
respectively. The time taken to achieve the 
peak concentration of oral CsA was 2.17 ± 
1.0 (ranging from 1.0 to 4.0) hours. 
During the first week (4 days postopera-
tively) after hepatectomy, ICG-Rmax and 
ICG-K were reduced by 57.7 ± 7.1 per cent 
(p<O.OOl) and 61.3 ± 9.7 per cent (p<O.OOI), 
respectively, and serum bilirubin was ele-
vated slightly by 0.71 ± 0.17 mg/ dl (p<0.05). 
This liver impairment was associated with a 
marked decrease in the CLs of intravenous 
CsA by 46.4 ± 7.8 per cent (p<O.OI). The 
AVC of intravenous CsA increased by 43.4 ± 
28.7 per cent (p<0.05). Although the bio-
availability of oral CsA decreased by 30.9 ± 
15.2 per cent (p<0.05), the AVC of oral CsA 
did not change significantly. 
Complete bile duct ligation also induced 
significant liver dysfunction. ICG-Rmax was 
reduced by 39.1 ± 12.8 per cent (p<0.005) 
and ICG-K was reduced by 65.6 ± 3.6 per 
cent (p<O.OOl) in the second week after 
surgery with a marked increase in serum 
bilirubin (5.80 ± 2.80 mg/ dl). During the 
same period, the CLs of intravenous CsA 
decreased by 21.6 ± 9.3 per cent (p<0.05). 
The AVC of intravenous CsA, however, did 
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Fig. 1. Comparison between the per cent changes in CsA kinetic parameters and ICG kinetic 
parameters following 70 per cent hepatectomy (4 days after operation) or complete bile duct 
ligation (l0 days after operation) in dogs. Although the ICG kinetics showed severe hepatic 
dysfunction after hepatectomy or complete bile duct ligation respectively, the systemic 
clearance of CsA have a significantly lower decreasing rate than that of the ICG kineti~sK Mter 
bile duct ligation, the percentage bio-availability reduced markedly. (mean ± standard 
deviation) 
0--0; the decreasing rates of maximal removal rate of indocyanine green (ICG-Rmax) 
.--e; the decreasing rates of plasma disappearance rate ofindocyanine green (ICG-K) 
.---11; the decreasing rates of total body clearance of CsA (CLs) 
.&-.&; the decreasing rates of per cent bioavailability (%F) 
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not change significantly, even though the 
leG kinetics indicated severe hepatic dys-
function. The AUe of oral esA decreased by 
69.0 ± 10.7 per cent (p<O.OOl) and the 
bioavailability also decreased markedly, by 
79.4 ± 6.1 per cent (p<O.OOI) (Fig. 1). 
DISCUSSION 
The liver is the major site of GsA metabo-
lism and GsA is extensively metabolized and 
eliminated in the bile. An analysis of bile by 
HPLG, however, revealed that less than 1 per 
cent of an administered dose of esA is 
excreted unchanged in the bile.s For the 
patient treated with GsA, therapeutic drug 
monitoring is necessary as it is difficult to 
assess individual variations in drug absorp-
tion, distribution, metabolism and elimina-
tion, which prevent GsA concentrations from 
being directly estimated by dose alone. This 
suggests that when a patient has hepatic 
--"---~-----~K-... --------------"-----------
--"--.. --~ ----,._------,.- ._-
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dysfunction, it will be much more difficult to 
establish a near-basal level of CsA and to 
maintain a steady condition because the 
patient needs CsA determination rapidly to 
change the actual amounts and inter-dose 
intervals of the CsA regimen in relation to 
the degree of the liver impairment and the 
cause of hepatic dysfunction, such as toxicity 
of CsA, rejection, ischemic damage, arterial 
thrombosis or biliary complication. 
Regarding the influence of liver dysfunc-
tion on CsA pharmacokinetics, Kahan l re-
ported that patients with impaired hepatic 
function cleared the drug one third more 
slowly, leading to an increased AUC, from a 
demographic analysis using radioimmunoas-
say measurement. However, since primary 
metabolites of CsA do not possess significant 
immuno-suppressant activity in animals9 and 
the deterioration of hepatic function secon-
dary to rejection or hepatic thrombosis fre-
quently produced a disproportionate rise in 
the radioimmunoassay blood concentration, 
the use of radioimmunoassay in the setting 
of altered hepatic function grossly under-
estimates the CsA dosage required to achieve 
the usual therapeutic level of the parent CsA 
compound. lO For these reasons, in our ex-
periments, we measured the CsA blood con-
centration using the HPLC method and 
whole blood to evaluate the parent com-
pound. 
Hepatic dysfunction created by hepatec-
tomy produced a 46 per cent reduction in 
CLs, a 43 per cent increase in AUC after 
intravenous CsA administration, and a pro-
longation of terminal halflife by 51 per cent. 
The bioavailability of oral CsA, however, 
decreased by 31 per cent, even though the 
AUC of oral CsA administration did not 
change significantly, which suggested that 
the oral CsA dosage regimen and the inter-
dose interval may not need to be changed 
immediately to intravenous administration. 
On the other hand, the hepatic impair-
ment created by bile duct ligation resulted in 
a different change in CsA kinetics compared 
to that created by hepatectomy. In spite of a 
22 per cent depression in systemic clearance, 
which correlated well with the ICG-Rmax 
decreasing rate due to the hepatic dysfunc-
tion, the bioavailability and AUC of oral CsA 
administration markedly decreased, presum-
ably due to the lack of sufficient bile salt for 
CsA absorption. Treatment should therefore 
be given rapidly by constant intravenous 
drugs or by double route therapy, in order to 
achieve the therapeutic level of the parent 
CsA compound. 
In fact, CsA malabsorption is common in 
the period immediately following OLTX and 
is associated with such problems as diarrhea, 
liver failure and externalized bile drainage. 
In a pediatric liver transplant patient, a 
bioavailability of less than 5 per cent was 
reported when a large amount of bile was 
eliminated from the T-tube and rejection 
occurred in the postoperative period. This 
patient needed an intravenous CsA dosage 
of up to 4 mg/kg and oral CsA 13.3 mg/kg 
(double route therapy) for maintaining ther-
apeutic blood levels of CsA.lO 
The assessment of hepatic dysfunction 
which influenced CsA kinetics has been 
reported, using elevated bilirubin levels. In 
this experiment, however, the serum biliru-
bin levels of the bile duct ligation dogs were 
about eight-times higher than the levels of 
the hepatectomized dogs, even though the 
hepatic dysfunction created by bile duct 
ligation was not as severe as that created by 
hepatectomy (the ICC-Rmax decreasing rate 
was 39 per cent in the bile duct ligation dogs 
and 58 per cent in the hepatectomized dogs, 
p<0.05). These data thus suggested that the 
serum bilirubin level is not a specific marker 
of liver dysfunction or drug metabolism. 
Moreover, we observed no significant differ-
ence in the prothrombin time or SCOT 
levels after either 70 per cent hepatectomy or 
bile duct ligation on the liver function test 
and there was no correlation between the 
prothrombin time or SCOT levels and the 
changes in CsA parameters. 
For the assessment of hepatic dysfunction, 
especially after hepatectomy, to study the 
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regeneration of the liver, ICG-Rmax is 
known to be one of the most accurate 
parameters of hepatic function and a highly 
sensitive index to hepatic cell damage.6 ICG-
K is also known as an index of functional 
hepatic blood flow which becomes reduced 
due to shunting or impaired hepatocellular 
function. 14 In this experiment the ICG-Rmax 
and ICG-K decreasing rates correlated well 
with the change in CsA kinetics. Mter 70 per 
cent hepatectomy, the ICG-Rmax decreasing 
rate correlated well with the systemic clear-
ance (r=0.668, p<O.Ol) and the ICG-K de-
creasing rate also correlated well with the 
bioavailability of oral CsA (r=0.667, p<O.OI). 
Concerning the correlation between the 
ICG kinetics and CsA kinetics after these 
hepatic injuries, although ICG kinetics 
showed severe hepatic dysfunction, the sys-
temic clearance of CsA was observed with a 
significantly lower decreasing rate than the 
ICG kinetic parameters (Fig. 1). This signifi-
cant discrepancy suggests that the pathway of 
metabolism and elimination between ICG 
and CsA could be different. ICG does not 
exhibit extrahepatic removal or enterohe-
patic circulation and it is not chemically 
altered during its transit through the liver,l5,16 
whereas CsA metabolism on the other hand, 
is circumstantially implicated by the mono-
oxygenase cytochrome P450." This compara-
tively low decreasing rate in the systemic 
clearance of CsA, however, can not be attri-
buted only to an increase in the capacity of 
remaining hepatocytes to metabolize CsA. 
There is also the possibility that CsA might 
be extensively distributed into peripheral 
body regions in the case of hepatic injuries, 
and the influence of the entero-hepatic cir-
culation of CsA should also be considered. IS 
The data in this experiment demonstrates 
that liver impairment significantly influences 
the pharmacokinetics of CsA, not only by 
changes in the intestinal absorption but also 
by changes in hepatic metabolism. Safe and 
effective therapy will require an improved 
understanding of how CsA pharmacokinetics 
very with the degree and cause of hepatic 
dysfunction. The dosage regimen should 
therefore be individualized in patients with 
hepatic impairment in order to maintain an 
adequate blood concentration of CsA. 
(Received for publication on Aug. 26, 1987) 
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